Llwytho...
Current approaches to incorporation of radium-223 in clinical practice
BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Prostate Cancer Prostatic Dis |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Publishing Group UK
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5895600/ https://ncbi.nlm.nih.gov/pubmed/29298991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-017-0020-y |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|